Lycium barbarum polysaccharides protect mice from hyperuricaemia through promoting kidney excretion of uric acid and inhibiting liver xanthine oxidase. (1st January 2020)

• Record Type: Journal Article
• Authors: Yu, Xin; Zhang, Lu; Zhang, Ping; Zhi, Jia; Xing, Ruinan; He, Lianqi
• Is Part Of: Pharmaceutical biology. Volume 58:Number 1(2020)
• Page Start: 944
• Page End: 949
• Publication Date: 2020-01-01
• Subjects: Organic anti-transporter 1 -- organic anti-transporter 3 -- glucose transporter 9; Pharmacognosy -- Periodicals; Materia medica, Vegetable -- Periodicals; 615.321
• DOI: 10.1080/13880209.2020.1817951
• Languages: English
• ISSNs: 1388-0209

Abstract

Abstract: Context: Lycium barbarum L. (Solanaceae) polysaccharides (LBPs) are important active constituents that have demonstrated kidney protection. Objective: This study investigated the effect of LBPs on hyperuricaemia and explored the underlying mechanism in mice. Materials and methods: Thirty-six C57BL/6 mice were randomly divided into the control group, hyperuricaemia group, allopurinol group (5 mg/kg) and three LBP groups (n = 6). The LBP groups were treated orally with LBPs at 50, 100 and 200 mg/kg body weight for 7 days. We examined the levels of serum uric acid (SUA ) and urinary uric acid (UUA ), as well as xanthine oxidase (XOD) activities. mRNA and protein were quantified by quantitative real-time PCR and Western blotting, respectively. Results: LBPs treatment (100 and 200 mg/kg) significantly reduced the SUA levels to 4.83 and 4.48 mg/dL, and markedly elevated the UUA levels to 4.68 and 5.18 mg/dL ( p < 0.05), respectively, while significantly increased the mRNA and protein expression levels of renal organic anti-transporter 1 (OAT1) and organic anti-transporter 3 (OAT3), and markedly decreased the levels of glucose transporter 9 (GLUT9) ( p < 0.05). Additionally, the serum XOD activities were reduced to 31.5 and 31.1 mU/mL, and the liver XOD activities were reduced to 80.6 and 75.6 mU/mL after treatment with 100 and 200 mg/kg LBPs ( p < 0.01), respectively. Discussion and conclusions: This study demonstrated the potential role of LBPs in reducing the uric acid level in hyperuricemic mice. A border study population should be evaluated. These results are valuable for the development of new anti-hyperuricaemia agents from LBPs.